Skip to content

MAZE MAZE Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Septerna, Inc. logo
Septerna, Inc.SEPN
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
Zymeworks logo
ZymeworksZYME
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's operating lease right-of-use assets in other assets?
MAZE (MAZE) reported operating lease right-of-use assets in other assets of $19.29M in Q1 2026.
How has MAZE's operating lease right-of-use assets in other assets changed year-over-year?
MAZE's operating lease right-of-use assets in other assets decreased by 14.2% year-over-year, from $22.48M to $19.29M.